MedTrace Logo

Methylphenidate in ADHD With Trichotillomania

NCT00552266 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2007-11-01

No results posted yet for this study

Summary

This study will evaluate the safety and effectiveness of methylphenidate in treating attention deficit hyperactivity disorder (ADHD) in children with both ADHD and trichotillomania.

Trichotillomania is an impulse control disorder. There is growing evidences of the involvement of dopaminergic neurotransmission in the pathophysiology of trichotillomania. Reported increase in the prevalence of ADHD among patients with impulse control disorders, such as pathological gambling as well as trichotillomania, may result from the overlapping pathophisiological background. It is hypothesized that in cases of ADHD comorbid with trichotillomania methtylphenidate treatment will exhibit beneficial effects in both the ADHD and the hair pulling.

Conditions

  • ADHD
  • Trichotillomania

Interventions

DRUG

Methylphenidate

tablets 10-60 mg/day administered once or twice daily 6 weeks

Sponsors & Collaborators

  • Clalit Health Services

    collaborator OTHER

  • Geha Mental Health Center

    lead OTHER

Principal Investigators

  • Pavel Golubchik, M.D. · Geha Mental Health Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Completion
2009-10-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00552266 on ClinicalTrials.gov